# ARMP catalysts: Armata Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/armp/catalysts

> Armata Pharmaceuticals, Inc. (ARMP) has no upcoming catalysts in this calendar. The latest recorded is the Armata Pharmaceuticals, Inc. earnings report, November 12, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Armata Pharmaceuticals, Inc. |
| Ticker | ARMP (NYSE) |
| SEC CIK | 921114 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/armp |

## Cash runway

Cash $18.3M as of 2026-09-30; quarterly burn $5.5M; about 10.0 months of runway at that rate (XBRL company facts, accession 0001104659-26-126277).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 17, 2021 | [Armata Pharmaceuticals, Inc. FDA approval](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed, approved | "On November 17, 2021, we announced that we had received approval from the FDA to proceed with our IND application for AP-SA02." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/921114/000155837024015530/armp-20240930x10q.htm)) |
| Mar 2023 | [Vancomycin Hydrochloride (vancomycin) topline data readout](https://sec-api.dev/pdufa/vancomycin) | ARMP |  | completed, positive | "Positive topline results from Phase 1b/2a trial ("SWARM-Pa") of inhaled AP-PA02 in patients with CF announced March 2023" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000110465925050219/tm2515395d1_ex99-2.htm)) |
| late 2024 | [Armata Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | scheduled | "We anticipate topline data from the Tailwind study by the end of 2024, followed by potential initiation of a pivotal bronchiectasis trial in 2025 in which we plan to evaluate inhaled AP-PA02 as an alternative to inhaled antibiotics in chronic pulmonary P. aeruginosa infections in subjects with NCFB." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/921114/000155837024015530/armp-20240930x10q.htm)) |
| November 13, 2024 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "Armata Pharmaceuticals Announces Third Quarter 2024 Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000155837024015526/armp-20241113xex99d1.htm)) |
| Q1 2025 | [Armata Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | scheduled | "Topline data anticipated in Q1 2025 to support potential initiation of a pivotal bacteremia efficacy trial in 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000110465924116327/tm2428148d1_ex99-1.htm)) |
| Q1 2025 | [Armata Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | scheduled | "Anticipating announcement of topline results from Phase 1b/2a diSArm study of intravenous AP-SA02 as a potential treatment for Staphylococcus aureus ("S. aureus") bacteremia in the first half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000155837025007752/armp-20250514xex99d1.htm)) |
| Q1 2025 | [Armata Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | scheduled | "We look forward to topline data in the first quarter of 2025 that should inform the optimal dose of AP-SA02 to be evaluated in a larger definitive efficacy study that we are planning to initiate in 2025."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000155837024015526/armp-20241113xex99d1.htm)) |
| March 20, 2025 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "LOS ANGELES, CA, March 20, 2025 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year ended December 31, 2024, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000155837025003405/armp-20250320xex99d1.htm)) |
| Q2 2025 | [Armata Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | scheduled | ""Topline data is anticipated in the second quarter of 2025 to support a potential future pivotal efficacy trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000155837025007752/armp-20250514xex99d1.htm)) |
| May 14, 2025 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000155837025007752/armp-20250514xex99d1.htm)) |
| May 19, 2025 | [Armata Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/armp/catalysts) | ARMP | antibiotic-resistant and difficult-to-treat bacterial infections, today | completed, positive | "On May 19, 2025, we announced positive topline data from the Phase 1b/2a diSArm study of intravenously administered AP-SA02 in complicated S. aureus bacteremia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/921114/000110465926126277/armp-20260930x10q.htm)) |
| August 11, 2025 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000155837025011227/armp-20250811xex99d1.htm)) |
| November 12, 2025 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000110465925110351/armp-20251112xex99d1.htm)) |
| March 25, 2026 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000110465926034523/armp-20260325xex99d1.htm)) |
| May 12, 2026 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000110465926060299/armp-20260512xex99d1.htm)) |
| 2H 2026 | [Methicillin trial start](https://sec-api.dev/pdufa/methicillin) | ARMP |  | scheduled | "Collectively, these milestones support the Company's planned initiation of its pivotal Phase 3 superiority study in the second half of 2026, designed to support a future Biologics License Application ("BLA") for AP-SA02." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000110465926084861/tm2620782d2_ex99-1.htm)) |
| August 12, 2026 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000110465926094896/armp-20260812xex99d1.htm)) |
| November 12, 2026 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000110465926126274/armp-ex99d1.htm)) |

## Drugs

- [Methicillin](https://sec-api.dev/pdufa/methicillin): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/armp/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ARMP catalysts: Armata Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/armp/catalysts

```bibtex
@misc{secapidev_companies_armp_catalysts_20261116,
  title        = {ARMP catalysts: Armata Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/armp/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_armp_catalysts_20261116","title":"ARMP catalysts: Armata Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/armp/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
